Résultats de la recherche
10
Tout
Rechercher les filtres
Mot-clé
concussion
New national survey finds most Americans unaware concussions are traumatic brain injuries
06 mars 2025 11h28 HE
|
Brain Injury Association of America
New national survey finds most Americans unaware concussions are traumatic brain injuries. Public misconceptions about brain injuries persist.
SportGait and Heads Together Health Merge to Form NeuroTech Insights, Transforming Neurofunctional Prehabilitation, Performance, and Recovery
11 févr. 2025 13h40 HE
|
NeuroTech Insights
NFL Legends Luke Kuechly & Merril Hoge Partner with AI-Driven Health Startup Revolutionizing TBI Assessment & Recovery
Oragenics, Inc. Provides Update on its Drug Intended to Treat Concussion and Non-Compliance with NYSE American Continued Listing Standards
16 août 2024 16h30 HE
|
Oragenics
SARASOTA, Fla., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN) ("the Company"), a company focused on developing unique, intranasal pharmaceuticals for the treatment of...
Oragenics Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range
14 août 2024 08h30 HE
|
Oragenics
• ONP-002 stability eliminates need for cumbersome cold storage• No FDA-approved pharmaceutical treatment available for concussion SARASOTA, Fla., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Oragenics,...
Oragenics, Inc. Announces Concussion Drug Successfully Completes FDA-Required Genotoxicity Study
12 août 2024 08h30 HE
|
Oragenics
– ONP-002 showed no cancer-causing DNA damage – Phase II clinical trial being planned SARASOTA, Fla., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on...
Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing
08 août 2024 08h45 HE
|
Oragenics
SARASOTA, Fla., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological...
Oragenics Improves Intranasal Drug Formulation for Treating Concussed Patients
10 juil. 2024 08h00 HE
|
Oragenics
SARASOTA, Fla., July 10, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological...
Oragenics Develops Automated Intranasal Device for Treating Concussed Patients
27 juin 2024 08h30 HE
|
Oragenics
SARASOTA, Fla., June 27, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological...
Oragenics, Inc. Announces Pricing of Public Offering
25 juin 2024 08h30 HE
|
Oragenics
SARASOTA, Fla., June 25, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological...
Oragenics, Inc. Announces Proposed Public Offering
24 juin 2024 18h43 HE
|
Oragenics
SARASOTA, Fla., June 24, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE: OGEN) (“Oragenics” or the “Company”), a company focused on developing unique, intranasal pharmaceuticals for the treatment of...